Subscribe to our Newsletters !!
Climate change is very disruptive to the Amazon ra
By 2024, there are certain things you need to do i
Insects that are given more attention and reverenc
Alembic Pharmaceuticals Limited appoints Mr. Manis
The importance of comparing the treatment of asthm
It is important to understand that natural remedie
Dear Readers, Welcome to the latest issue of The Magazine
Sartorius introduced Sartolab® RF|BT 150-1000 vacuum filtration units that the new design has been improved to offer greater capacity and speedier and greater physical stability for a wide range of sample types.
Design modifications include:
1.An increase of the membrane surface area to facilitate optimal filtration
2.Replacement of the 0.45 μm cellulose acetate membrane with a 0.45 μm polyethersulfone
3.membrane to increase the flow rate while keeping the same low protein binding properties
4.An optimized center of gravity to increase stability of the units
5.Direct use on the Sartolab® Multistation for parallel filtration
“We are excited to introduce our updated Sartolab® vacuum filtration units which build upon the benefits and ergonomic design of the original units,” said Catherine Leluan, Product Manager. “The redesign of these units exemplifies our commitment to engineer products that accelerate and streamline workflows, are user-friendly and are well-suited for the busy laboratory setting. In addition, improvement in our manufacturing controls are expected to lead to increased robustness of supply to help meet growing market demand.”
Sartolab® RF|BT vacuum filtration units are made to be used for research and for filtration of small volumes ranging from 50 mL up to 1L. Sartolab® RF units come with a receiver flask that connects to the filtration funnel. The Sartolab® BT design includes only the bottles top filter (filtration funnel) that allows users to make use of their own flasks to filter their receivers, and/or increase the filtration capacity according to the amount of particles in the liquid that is being filtered by filling multiple flasks for receivers.
1.Redesigned units provide faster, higher capacity and greater physical stability for a wide range of sample types 2.Larger membrane surface area facilitates optimal filtration 3.Use of polyethersulfone membrane in the 0.45 μm pore size filter increases the flow rate with the same low protein binding properties
1.Redesigned units provide faster, higher capacity and greater physical stability for a wide range of sample types
2.Larger membrane surface area facilitates optimal filtration
3.Use of polyethersulfone membrane in the 0.45 μm pore size filter increases the flow rate with the same low protein binding properties
These filtration units provide the best flow rates and have huge filtration areas and a low affinity protein membrane that minimizes loss of protein and a membrane that is optimized for a smaller hold-up volume.
The Sartolab® RF|BT vacuum filtration units are available in three different pore sizes to meet most of the applications:
1.1 μm for mycoplasma removal
2.22 μm for sterile filtration of cell culture media, buffers, and reagents
3.45 μm for clarification of aqueous and viscous solutions
Sartolab® RF|BT products are now manufactured in a new plant designed to meet growing market demand for vacuum filtration units. The plant is ISO 13485 certified, and an ISO Class 8 cleanroom assures the highest level of sterility.
Improved efficiency of logistics during manufacture combined with improved storage processes has reduced the carbon footprint required for global distribution of these units by 99%.
For further information : Sartolab® RF|BT products
A profile of Sartorius
The Sartorius Group is a leading international partner of life science research and the biopharmaceutical industry.
With innovative laboratory instruments and consumables, the Group’s Lab Products & Services Division concentrates on serving the needs of laboratories performing research and quality control at pharma and biopharma companies and those of academic research institutes. The Bioprocess Solutions Division with its broad product portfolio focusing on single-use solutions helps customers to manufacture biotech medications and vaccines safely and efficiently.
The Group has been annually growing by double digits on average and has been regularly expanding its portfolio by acquisitions complementary technologies. In fiscal 2020, the company earned sales revenue of some 2.34 billion euros. At the end of 2020, nearly 11,000 people were employed at the Group’s approximately 60 manufacturing and sales sites, serving customers around the globe.
For more information: : Contact us
